In contrast, vorinostat increased the expression of p53, but was equally effective against wt p53 and p53-deleted colon cancer cells, whereas the efficacy of class-I-selective inhibitor entinostat was dependent on p53 status [91]. The gene discussed is TP53; the disease is malignant colon neoplasm.